Biochemical Pharmacology volume 80, issue 5, P666-673 2010 DOI: 10.1016/j.bcp.2010.03.001 View full text
Sreenath V. Sharma, Jeff Settleman

Abstract: Rational approaches to targeted cancer therapy have begun to predominate the pipelines of oncology drug development. Our rapidly increasing understanding of the "wiring" of tumor cells and the vulnerabilities of such cells that can potentially be exploited through targeted treatments has opened up enormous opportunities for improved therapies. Accumulating evidence suggests that many of these vulnerabilities reflect states of dependency or "addiction" that are unique to cancer cells (versus normal cells). Such…

expand abstract